The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

Credit: Rembolle via Shutterstock. Novo Nordisk has secured approval from the US Food and Drug Administration (FDA) for Alhemo (concizumab-mtci) as a once-daily treatment to prevent or reduce bleeding ...